Pharmadrug Announces Positive Research Results of Cepharanthine to Treat Multiple Cancers

CANNANNEW REPORT

Validates Cepharanthine’s potential in treating various cancers with unsatisfactory treatment options Positions Cepharanthine’s ‘pipeline in a pill’ strategy focusing on esophageal, colorectal, liver and skin cancers Advance to FDA IND-enabling studies to support human clinical studies   Toronto, Ontario–(Newsfile Corp. – July 28, 2021) – PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce the completion of their preclinical cancer study which evaluated cepharanthine-2HCl, the active pharmaceutical ingredient in PD-001, the Company’s patented oral formulation of cepharanthine. The results from the study validate cepharanthine’s potential in treating different types of cancer including esophageal, colorectal, liver and skin. The results also provide confidence in the Company’s plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. The study was conducted by a respected contract research organization with deep expertise in preclinical oncology model development and drug testing and data corresponding to all studied cancer cell lines have now been reported to the Company.   PharmaDrug was pleased to find that twenty of the sixty cancer cells lines screened showed growth inhibition of at least fifty percent when exposed to cepharanthine levels previously determined to be well tolerated in a human clinical population. Additionally, there were several instances in which cepharanthine displayed growth inhibition which was comparable or superior to current gold standard treatments, including colorectal, liver and skin cancers. More notably, results of the current study demonstrated that esophageal cancer was the most highly responsive of all sixty cancers examined; with cepharanthine showing 99.96% growth inhibition at the top concentration tested and displayed approximately 5-times greater potency (at IC50) than cisplatin, a…

Excerpt only …
READ MORE BELOW
Source : Pharmadrug Announces Positive Research Results of Cepharanthine to Treat Multiple Cancers

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.